Patients with diabetes mellitus have> 2× the risk for developing heart failure (HF; HF with
reduced ejection fraction and HF with preserved ejection fraction). Cardiovascular …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …

Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular
disease. The strong connection between the severity of hyperglycaemia, metabolic changes …

Background Metabolic syndrome and related metabolic disturbances represent a state of
low-grade inflammation, which accelerates insulin resistance, type 2 diabetes (T2D) and …

ABSTRACT Introduction: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally
considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered …

Despite being first described 45 years ago, the existence of a distinct diabetic
cardiomyopathy remains controversial. Nonetheless, it is widely accepted that the diabetic …

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing.
Cardiovascular disease continues to be the leading cause of death in patients with T2DM …

Diabetes is one of the chronic metabolic disorders which poses a multitude of life-
debilitating challenges, including cardiac muscle impairment, which eventually results in …